Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Engineered immune cells take on deadly childhood brain cancer

NCT ID NCT07513194

First seen Apr 21, 2026 · Last updated May 12, 2026 · Updated 5 times

Summary

This early-phase trial tests a new treatment for children with a rare and aggressive brain tumor called atypical teratoid rhabdoid tumor (ATRT) that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, modified in the lab to better recognize and attack the tumor, plus added signals to help them survive longer. The main goals are to find the safest dose and check for side effects, while also seeing if the cells can shrink the tumor.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATYPICAL TERATOID/RHABDOID TUMOR are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Texas Children's Hospital

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.